Monte Rosa Therapeutics, Inc.

GLUE

Monte Rosa Therapeutics, Inc.

GLUE

Insider Sentiment (TTM):

Last Purchase:2025-03-24Last Sale:2026-06-29Shares Purchased (TTM):0Shares Sold (TTM):145,544

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:79,560,950Shares Outstanding:99,883,878Institutional Ownership Pct.:79.65%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	90	160	130	208	69	79	224	126	109	100	128	59
Marketable Securities	531	506	247	183	221	248	148	117	153	93	104	119
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	9	-	-	-
Other Receivables	-	5	5	5	2	1	0	1	1	1	1	0
Prepaid Expense And Other Assets Current	5	7	4	6	7	5	5	8	6	6	3	4
Assets Current	631	678	393	402	299	332	377	251	278	199	236	183
Restricted Cash Current	-	-	-	-	-	-	-	-	-	-	0	0
Property Plant And Equipment Net	30	28	26	28	29	29	29	31	33	34	34	35
Operating Lease Right Of Use Asset	24	25	24	25	26	26	27	27	28	28	29	29
Restricted Cash Noncurrent	5	5	5	5	5	5	5	5	5	5	5	5
Other Assets Noncurrent	1	1	0	0	0	0	0	0	0	0	0	0
Assets	691	736	449	460	360	393	439	315	344	267	304	252
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	7	8	4	15	6	6	17	4	6	7	11	6
Accounts Payable And Other Accrued Liabilities Cur…	26	26	27	18	14	16	19	15	13	11	15	14
Deferred Revenue Current	22	33	30	25	18	33	117	19	20	20	18	-
Operating Lease Liability Current	5	4	4	4	4	4	4	4	3	3	3	3
Liabilities Current	60	71	64	61	42	59	157	42	42	41	47	23
Deferred Revenue	106	104	111	112	8	17	16	25	34	29	32	-
Defined Benefit Pension Plan Liabilities Noncurren…	5	5	5	5	5	4	4	3	3	3	3	1
Operating Lease Liability Noncurrent	33	35	35	36	37	38	39	40	41	42	43	44
Liabilities	204	215	216	214	92	118	216	110	119	114	125	68
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,058	1,048	714	680	675	670	665	660	656	553	548	519
Accumulated Other Comprehensive Income Loss Net Of…	-5	-5	-4	-3	-3	-3	-3	-2	-3	-3	-3	-1
Retained Earnings Accumulated Deficit	-565	-522	-477	-431	-404	-392	-439	-452	-428	-398	-366	-333
Stockholders Equity	487	522	233	246	268	275	223	205	225	153	179	185
Liabilities And Stockholders Equity	691	736	449	460	360	393	439	315	344	267	304	252
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	-	-	0	0
Common Stock Shares Authorized	500	500	500	500	500	500	500	500	500	500	500	500
Common Stock Shares Issued	85	84	66	62	62	62	62	61	61	50	50	50
Shares Outstanding	85	84	66	62	62	62	62	61	61	50	50	50

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.50%	12.52%	14.99%	-	-	-	-	-	-	-	-	-
2025	-0.95%	9.00%	34.36%	13.48%	77.07%	163.36%	24.29%	32.90%	75.56%	9.05%	20.96%	2.12%
2024	-20.46%	-27.80%	-9.85%	55.03%	29.90%	22.86%	8.71%	-25.92%	-42.08%	-40.23%	-42.07%	-29.04%
2023	-	-	-	-7.19%	-28.29%	-58.38%	-5.45%	71.21%	64.55%	16.09%	-7.22%	-32.35%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	10.58	9.54	6.12	6.54	7.16	5.61	2.40	6.03	6.56	4.82	5.07	8.09
Quick Ratio	10.49	9.44	6.05	6.45	7.00	5.53	2.37	5.83	6.42	4.69	5.00	7.91
Working Capital	571.75M	606.51M	328.97M	340.37M	257.61M	273.06M	220.49M	209.57M	235.55M	157.74M	189.62M	160.30M
Leverage & Debt
Debt to Equity	0.42	0.41	0.93	0.87	0.34	0.43	0.97	0.53	0.53	0.75	0.69	0.37
Interest Coverage TTM	-10.14	-9.82	-4.19	0.72	1.25	-0.18	-7.68	-12.47	-14.41	-15.42	-15.35	-15.74
Debt Ratio	0.29	0.29	0.48	0.47	0.25	0.30	0.49	0.35	0.35	0.43	0.41	0.27
Efficiency & Turnover
Asset Turnover TTM	0.05	0.08	0.28	0.47	0.51	0.48	0.20	0.05	0.02	0.00	0.00	0.00
Days Sales Outstanding TTM	-	-	-	-	-	-	-	-	570.41	-	-	-
Receivables Turnover TTM	-	-	-	-	-	-	-	-	0.64	-	-	-
Per Share Metrics
Diluted EPS TTM	-1.59	-1.30	-0.46	0.25	0.29	0.07	-0.98	-1.46	-1.83	-2.25	-2.63	-2.67
Free Cash Flow Per Share TTM	-0.39	-0.20	-0.33	2.33	0.86	0.37	0.51	-0.77	-0.95	-1.16	-1.22	-2.45
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-633.04%	-345.21%	-43.83%	4.69%	8.40%	-1.33%	-107.26%	-861.30%	-2,420.91%	-13,533.74%	-	-
Net Profit Margin TTM	-560.85%	-302.69%	-31.23%	11.54%	13.58%	3.86%	-96.14%	-797.26%	-2,264.53%	-12,714.47%	-	-
Growth Metrics
Net Revenue Growth (1Y)	-83.86%	-73.07%	63.54%	1,112.27%	2,990.57%	14,889.38%	-	-	-	-	-	-
Net Income Growth (1Y)	-766.65%	-2,213.02%	-46.87%	-117.54%	-118.53%	-104.55%	-46.29%	-10.15%	4.07%	16.02%	24.75%	17.14%
EPS Growth (1Y)	-639.91%	-1,837.84%	-52.73%	-117.46%	-116.06%	-103.33%	-62.65%	-45.43%	-27.78%	-4.83%	14.63%	9.89%
Valuation Metrics
P/E TTM	-15.24	-12.64	-33.72	29.15	15.34	61.95	-7.06	-3.64	-2.04	-3.13	-2.15	-1.80
P/B TTM	5.04	3.15	5.59	2.48	1.38	1.39	2.30	2.12	1.19	2.78	1.62	1.29
P/S TTM	85.49	38.25	10.53	3.36	2.08	2.39	6.78	29.03	46.26	398.59	-	-
Market Cap	2.46B	1.64B	1.30B	610.57M	370.66M	381.17M	512.94M	434.66M	266.42M	424.10M	290.39M	238.61M
Enterprise Value	2.36B	1.48B	1.17B	397.27M	296.28M	297.76M	283.82M	304.18M	152.70M	319.49M	157.71M	175.04M
Calculated Values
Free Cash Flow TTM	-39.92M	-19.66M	-27.50M	192.10M	70.93M	30.48M	38.01M	-62.79M	-67.76M	-69.81M	-62.84M	-122.02M
Net Debt	-95.04M	-164.81M	-134.84M	-213.29M	-74.38M	-83.41M	-229.12M	-130.48M	-113.71M	-104.62M	-132.68M	-63.58M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Janku, Filip

Title: Chief Medical Officer

Shares: 6,000

Price/Share: $22.95

Value: $137,700.00

Shares Owned: 59,992

Relationship: Officer

Ownership: Direct

2026-06-29Sale

Owner: Manning, Anthony M.

Title: -

Shares: 10,000

Price/Share: $23.11

Value: $231,100.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-06-24Sale

Owner: Janku, Filip

Title: Chief Medical Officer

Shares: 30,000

Price/Share: $21.42

Value: $642,600.00

Shares Owned: 59,992

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Townson, Sharon

Title: Chief Scientific Officer

Shares: 3,000

Price/Share: $20.00

Value: $60,000.00

Shares Owned: 67,845

Relationship: Officer

Ownership: Direct

2026-06-23Sale

Owner: Champoux, Jennifer

Title: Chief Operating Officer

Shares: 2,175

Price/Share: $20.00

Value: $43,500.00

Shares Owned: 62,371

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Janku, Filip	Officer	Chief Medical Officer	Direct	Sale	6,000	22.95	$137,700.00	59,992	4
2026-06-29	Manning, Anthony M.	Director	-	Direct	Sale	10,000	23.11	$231,100.00	0	4
2026-06-24	Janku, Filip	Officer	Chief Medical Officer	Direct	Sale	30,000	21.42	$642,600.00	59,992	4
2026-06-23	Townson, Sharon	Officer	Chief Scientific Officer	Direct	Sale	3,000	20.00	$60,000.00	67,845	4
2026-06-23	Champoux, Jennifer	Officer	Chief Operating Officer	Direct	Sale	2,175	20.00	$43,500.00	62,371	4
2026-06-17	Champoux, Jennifer	Officer	Chief Operating Officer	Direct	Sale	2,176	19.00	$41,344.00	62,371	4
2026-06-17	Townson, Sharon	Officer	Chief Scientific Officer	Direct	Sale	3,000	19.00	$57,000.00	67,845	4
2026-06-01	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	5,466	19.57	$106,969.62	594,538	4
2026-05-29	Townson, Sharon	Officer	Chief Scientific Officer	Direct	Sale	6,000	19.87	$119,220.00	67,845	4
2026-05-27	Champoux, Jennifer	Officer	Chief Operating Officer	Direct	Sale	2,175	20.00	$43,500.00	62,371	4
2026-05-22	Champoux, Jennifer	Officer	Chief Operating Officer	Direct	Sale	2,176	19.00	$41,344.00	62,371	4
2026-05-21	Manning, Anthony M.	Director	-	Direct	Sale	10,000	18.01	$180,100.00	0	4
2026-05-01	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	5,467	18.92	$103,435.64	600,004	4
2026-04-14	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	8,000	17.64	$141,120.00	605,471	4
2026-04-09	Nickson, Philip	Officer	Chief Business & Legal Officer	Direct	Sale	5,845	17.69	$103,398.05	55,000	4
2026-03-04	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	139	17.96	$2,496.44	22,554	4
2026-03-02	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	536	17.50	$9,380.00	22,693	4
2026-03-02	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	5,466	17.92	$97,950.72	613,471	4
2026-02-23	Janku, Filip	Officer	Chief Medical Officer	Direct	Sale	9,189	19.50	$179,185.50	65,837	4
2026-01-07	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	5,466	23.90	$130,637.40	618,937	4
2026-01-05	Townson, Sharon	Officer	Chief Scientific Officer	Direct	Sale	3,155	15.17	$47,861.35	67,845	4
2026-01-05	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	1,039	15.17	$15,761.63	22,693	4
2026-01-05	Warmuth, Markus	Director,Officer	President & CEO	Direct	Sale	10,135	15.17	$153,747.95	624,403	4
2026-01-05	Janku, Filip	Officer	Chief Medical Officer	Direct	Sale	3,155	15.17	$47,861.35	75,026	4
2026-01-05	Champoux, Jennifer	Officer	Chief Operating Officer	Direct	Sale	2,629	15.17	$39,881.93	62,371	4
2026-01-05	Nickson, Philip	Officer	Chief Business & Legal Officer	Direct	Sale	3,155	15.17	$47,861.35	60,845	4
2025-06-03	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	2,062	4.45	$9,175.90	23,732	4
2025-03-24	Leo, Chandra P.	Director	-	Direct	Purchase	10,000	5.84	$58,400.00	10,000	4
2024-10-29	Versant, Venture Capital …	TenPercentOwner	-	Indirect	Sale	67,905	9.25	$628,121.25	1,573,453	4
2024-09-20	Versant, Venture Capital …	TenPercentOwner	-	Direct	Sale	1,132,566	6.53	$7,395,655.98	5,099,336	4
2024-09-13	Versant, Ventures Vi Gp, …	TenPercentOwner	-	Direct	Sale	9,269	6.16	$57,097.04	6,231,902	4
2024-07-05	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	1,610	3.83	$6,166.30	13,944	4
2024-06-03	Dunn, Edmund	Officer	Principal Accounting Officer	Direct	Sale	1,207	4.04	$4,876.28	15,554	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

79.65%

Inst. Shares: 79,560,950

Shares Outstanding: 99,883,878

2025-12-31

70.20%

Inst. Shares: 58,318,548

Shares Outstanding: 83,071,185

2025-09-30

65.87%

Inst. Shares: 54,276,829

Shares Outstanding: 82,397,753

2025-06-30

66.42%

Inst. Shares: 54,591,489

Shares Outstanding: 82,186,768

2025-03-31

63.24%

Inst. Shares: 51,954,906

Shares Outstanding: 82,148,719

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	79,560,950	99,883,878	79.65%
2025-12-31	58,318,548	83,071,185	70.20%
2025-09-30	54,276,829	82,397,753	65.87%
2025-06-30	54,591,489	82,186,768	66.42%
2025-03-31	51,954,906	82,148,719	63.24%
2024-12-31	53,441,063	73,910,026	72.31%
2024-09-30	42,132,246	82,011,670	51.37%
2024-06-30	39,409,842	71,233,992	55.32%
2024-03-31	34,320,547	60,156,187	57.05%
2023-12-31	34,641,451	51,396,961	67.40%
2023-09-30	37,373,069	49,814,903	75.02%
2023-06-30	35,040,768	49,431,922	70.89%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Monte Rosa Therapeutics, Inc. (GLUE) — SEC Financial Statements & Analysis

Monte Rosa Therapeutics, Inc. (GLUE) is a biological products, (no diagnostic substances) company, incorporated in DE. Monte Rosa Therapeutics, Inc. trades on Nasdaq as: GLUE. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Monte Rosa Therapeutics, Inc. reported a -83.86% year-over-year revenue growth, a Debt-to-Equity ratio of 0.42x, a Price-to-Sales (P/S) ratio of 85.49x (TTM), a Price-to-Book (P/B) ratio of 5.04x (TTM), at a market cap of $2.46B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -83.86%
Debt To Equity: 0.42x
P/S TTM: 85.49x
P/B TTM: 5.04x
Market Cap: $2.46B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Monte Rosa Therapeutics, Inc. in?

Monte Rosa Therapeutics, Inc. (GLUE) operates in the Biological Products, (No Diagnostic Substances) industry.

What is GLUE's market cap?

Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $2.46B as of 2026-06-30.

What exchange does GLUE trade on?

Monte Rosa Therapeutics, Inc. (GLUE) trades on the Nasdaq.

Where is Monte Rosa Therapeutics, Inc. incorporated?

Monte Rosa Therapeutics, Inc. is incorporated in DE.